quadrangularin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
quadrangularin A : An indane-derived stilbenoid that is a homodimer obtained by cyclodimerisation of resveratrol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5318096 |
| CHEMBL ID | 2335820 |
| CHEBI ID | 76192 |
| SCHEMBL ID | 3652138 |
| MeSH ID | M000612081 |
| Synonym |
|---|
| (1e,2r,3r)-2-(3,5-dihydroxyphenyl)-3-(4-hydroxyphenyl)-1-[(4-hydroxyphenyl)methylidene]-2,3-dihydroindene-4,6-diol |
| CHEMBL2335820 |
| (+/-)-quadrangularin a |
| chebi:76192 , |
| SCHEMBL3652138 |
| quadrangularin a |
| (1e,2r,3r)-2-(3,5-dihydroxyphenyl)-1-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)-2,3-dihydro-1h-indene-4,6-diol |
| cyphostemmin b |
| BIQMSWPBPAKGSE-PBSLAQMISA-N |
| Q7268318 |
| DTXSID301030542 |
| 252557-25-8 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| antioxidant | A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| indanes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID761533 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM treated 2 hrs before LPS challenge measured after 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| AID1246397 | Agonist activity at ERbeta (248 to 510 amino acid residues) (unknown origin) assessed as induction of interaction with SRC1 after 24 hrs by yeast two-hybrid assay relative to isopaucifloral F | 2015 | European journal of medicinal chemistry, Sep-18, Volume: 102 | Synthesis, estrogenic activity, and anti-osteoporosis effects in ovariectomized rats of resveratrol oligomer derivatives. |
| AID1246398 | Antagonist activity at ERbeta (248 to 510 amino acid residues) (unknown origin) assessed as inhibition of E2 induced interaction with SRC1 after 24 hrs by yeast-two-hybrid assay | 2015 | European journal of medicinal chemistry, Sep-18, Volume: 102 | Synthesis, estrogenic activity, and anti-osteoporosis effects in ovariectomized rats of resveratrol oligomer derivatives. |
| AID1246396 | Antagonist activity at ERalpha (301 to 553 amino acid residues) (unknown origin) assessed as inhibition of E2 induced interaction with SRC1 after 24 hrs by yeast-two-hybrid assay | 2015 | European journal of medicinal chemistry, Sep-18, Volume: 102 | Synthesis, estrogenic activity, and anti-osteoporosis effects in ovariectomized rats of resveratrol oligomer derivatives. |
| AID735992 | Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of paraquat-induced cell death at 10 uM incubated for 2 hrs prior to paraquat challenge measured after 24 hrs by MTT assay (Rvb = 62.05 +/- 0.47%) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis and biological evaluation of novel neuroprotective agents for paraquat-induced apoptosis in human neuronal SH-SY5Y cells. |
| AID1246395 | Agonist activity at ERalpha (301 to 553 amino acid residues) (unknown origin) assessed as induction of interaction with SRC1 after 24 hrs by yeast two-hybrid assay relative to isopaucifloral F | 2015 | European journal of medicinal chemistry, Sep-18, Volume: 102 | Synthesis, estrogenic activity, and anti-osteoporosis effects in ovariectomized rats of resveratrol oligomer derivatives. |
| AID761532 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||